# Regulatory Barriers Delay Clinical Access to Rapid Drug Testing Tools Emergency physicians lack bedside testing for emerging synthetic substances due to strict FDA regulations. - **Source:** [TIME](https://time.com/) - **Published:** 2026-11-01 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/5360ae01-e2d7-4734-9765-d869abb436b7 ## Rapidly Evolving Drug Supply The illicit drug market has shifted significantly since 2020, introducing substances like nitazenes, medetomidine, and cychlorphine. These novel synthetics appear in rapid succession, often outpacing existing medical detection capabilities. While forensic testing tools exist, they remain largely unavailable for clinical use, leaving physicians to treat patients without knowing the specific substances involved. ## Regulatory Divide in Testing Current rapid tests are frequently labeled for forensic use only, preventing their application in clinical settings. To be used at the bedside, tests must secure FDA approval as diagnostic tools and meet CLIA-waived status. This regulatory framework creates a stark contrast where law enforcement accesses data that emergency physicians cannot. ## Clinical Impact of Xylazine Xylazine, which spread through the fentanyl supply starting in 2020, presents unique clinical challenges. It does not respond to naloxone, leaving patients dangerously sedated or unstable after opioid reversal. Furthermore, it is linked to necrotic skin wounds and complex withdrawal syndromes, complicating standard treatment protocols for emergency room medical staff. ## Medetomidine and Cardiovascular Risks Medetomidine has recently overtaken xylazine supplies, causing profound sedation and cardiovascular instability. Withdrawal can trigger extreme hypertension and tachycardia within hours, potentially leading to heart attacks in younger patients. Clinicians currently lack point-of-care tests for these substances, forcing reliance on outdated public health alerts rather than real-time patient data. ## Information Silos in Healthcare Data regarding emerging drugs is currently trapped in silos, derived primarily from law enforcement seizures and autopsy reports. This system identifies new substances in deceased individuals long before clinicians can detect them in living patients. Consequently, emergency departments operate with significant information gaps, hindering effective treatment and patient discharge planning. ## Proposed Expedited FDA Pathway The FDA should establish an expedited pathway for clinical tests targeting emerging drug threats identified by public health agencies. By prioritizing and adapting existing dual-pathway frameworks, the agency could bypass ordinary, lengthy timelines. This would allow manufacturers to seek special clearance and CLIA waivers simultaneously, addressing urgent public health needs more effectively. ## Addressing Market Economic Gaps The economics of emerging drugs are volatile, as substances often disappear before manufacturers can justify extensive clinical studies. Federal and state agencies could bridge this funding gap by supporting independent validation of rapid tests. A small commercial market for a specific test does not diminish the critical public health necessity. ## Integrating Bedside Diagnostic Tools Point-of-care testing should be treated as a presumptive tool, similar to other imperfect diagnostic inputs like physical exams. Integrating these tests into emergency departments would provide an early-warning system for the overdose crisis. Providing physicians with these tools ensures they can make informed decisions when every minute is essential for survival. ## Sources covering this story - https://time.com/article/2026/11/01/why-doctors-are-last-to-know-what-s-in-the-drug-supply/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._